VaxForm

VaxForm specializes in the development of vaccine formulations. Press Releases: 01Sep2020 - VaxForm was awarded a NSF SBIR Phase I grant to develop a COVID-19 vaccine using their oral delivery platform. 11Oct2016 - VaxForm has published the results of their non-clinical safety evaluation of their vaccine targeting S.pyogenes in the Journal of Applied Toxicology. The article citation is: Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant. Harm HogenEscha, Anisa Dunham, Elodie Burlet, Fangjia Lu, Yung-Yi C. Mosley and Garry Morefield. J Applied Toxicology 2016 01Jul2014 - VaxForm has published the results of their pre-clinical development studies for their vaccine targeting S.pyogenes in the journal Vaccine. The article demonstrates the potency and stability optimization that has been achieved during formulations development. The article citation is: Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes, Vaccine 32 (2014), pp. 3810-3815. 28May2014 - VaxForm & EMD Millipore present a poster entitled "Tangential Flow Filtration Application for the Purification and Production of S. pyogenes vaccine from E. Coli inclusion bodies" at the 2014 AAPS National Biotechnology Conference in San Diego, CA. In this work, Vaxform LLC and EMD Millipore have collaborated to develop membrane-based unit operations for the purification of inclusion bodies from a bacterial expression system. The product being purified was a recombinant fusion protein antigen targeting S. pyogenes.